GlassScriptPhysician profile
Kevin Y Chu
NPI 1790147247
$16,796.54
in general payments reported to CMS, 2019-2025
27 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $60.60 · 2021: $1,544 · 2022: $2,693 · 2023: $2,581 · 2024: $8,376 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,604 · Consulting Fee: $3,780 · Travel and Lodging: $2,578 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,604.23 |
| Consulting Fee | $3,780.00 |
| Travel and Lodging | $2,578.39 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $6,438.23 | 2019-2024 | Xiaflex |
| Boston Scientific Corporation | $4,162.72 | 2019-2023 | |
| Coloplast Corp | $2,934.78 | 2019-2025 | Titan, Speedicath |
| Astellas Pharma US INC | $477.93 | 2023-2024 | Xtandi |
| Abbvie INC. | $436.35 | 2022-2024 | Lupron Depot, Botox |
| Pfizer INC. | $278.16 | 2023-2024 | |
| Endo USA, INC. | $277.66 | 2024 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $265.47 | 2023-2024 | Prolaris |
| Aytu Biopharma, INC. | $185.72 | 2019 | |
| Sumitomo Pharma America, INC. | $170.44 | 2023-2024 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $159.87 | 2023-2024 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $156.84 | 2023 | |
| Acerus Pharmaceuticals Corporation | $154.67 | 2021 | |
| Merck Sharp & Dohme LLC | $105.75 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Urogen Pharma, INC. | $82.96 | 2020-2023 | Jelmyto |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $81.13 | 2019 | |
| Tolmar, INC. | $76.94 | 2023-2024 | |
| Hollister Incorporated | $52.00 | 2022-2023 | Vapro Pocket |
| Antares Pharma, INC. | $50.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $45.99 | 2023 | |
| Myovant Sciences INC. | $44.64 | 2022 | |
| Progenics Pharmaceuticals, INC. | $44.34 | 2024 | |
| Blue Earth Diagnostics | $26.35 | 2023 | |
| Procept Biorobotics Corporation | $25.68 | 2024 | Aquabeam System |
| Urovant Sciences INC | $23.97 | 2022 | |
| Agiliti Surgical, INC. | $23.70 | 2023 | Trinity, Sonablate |
| Sagent Pharmaceuticals | $14.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.